JP2005537244A

JP2005537244A - 療法化合物の粘膜搬送を増進させるための、上皮接合部接着分子の生理機能を調節する組成物および方法

療法化合物の粘膜搬送を増進させるための、上皮接合部接着分子の生理機能を調節する組成物および方法 Download PDF

Info

Publication number: JP2005537244A
Authority: JP; Japan
Prior art keywords: jam; peptide; seq; protein; agent
Prior art date: 2002-06-28
Legal status : Withdrawn

Application number

JP2004517800A

Other languages

English (en)

Japanese (ja)

Other versions

JP2005537244A5 (https=

Inventor

クワ，スティーブン・シー

Original Assignee

ナステック・ファーマシューティカル・カンパニー・インコーポレーテッド

Priority date

2002-06-28

Filing date

2003-06-24

Publication date

2005-12-08

2003-06-24 Application filed by ナステック・ファーマシューティカル・カンパニー・インコーポレーテッド filed Critical ナステック・ファーマシューティカル・カンパニー・インコーポレーテッド

2005-12-08 Publication of JP2005537244A publication Critical patent/JP2005537244A/ja

2006-08-03 Publication of JP2005537244A5 publication Critical patent/JP2005537244A5/ja

Status Withdrawn legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims abstract description 156
239000000203 mixture Substances 0.000 title claims abstract description 97
150000001875 compounds Chemical class 0.000 title claims description 55
230000001225 therapeutic effect Effects 0.000 title claims description 35
230000035790 physiological processes and functions Effects 0.000 title claims description 4
230000002708 enhancing effect Effects 0.000 title description 8
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 600
108090000623 proteins and genes Proteins 0.000 claims abstract description 272
102000004169 proteins and genes Human genes 0.000 claims abstract description 270
239000013543 active substance Substances 0.000 claims abstract description 161
102000003940 Occludin Human genes 0.000 claims abstract description 96
108090000304 Occludin Proteins 0.000 claims abstract description 96
108050009302 Claudin Proteins 0.000 claims abstract description 91
102000002029 Claudin Human genes 0.000 claims abstract description 90
230000027455 binding Effects 0.000 claims abstract description 44
230000035479 physiological effects, processes and functions Effects 0.000 claims abstract description 16
102000004196 processed proteins & peptides Human genes 0.000 claims description 224
229940024606 amino acid Drugs 0.000 claims description 187
150000001413 amino acids Chemical class 0.000 claims description 185
108010040135 Junctional Adhesion Molecule C Proteins 0.000 claims description 97
108010064064 Junctional Adhesion Molecules Proteins 0.000 claims description 81
102000014748 Junctional Adhesion Molecules Human genes 0.000 claims description 81
239000008194 pharmaceutical composition Substances 0.000 claims description 77
125000003275 alpha amino acid group Chemical group 0.000 claims description 72
102100023429 Junctional adhesion molecule C Human genes 0.000 claims description 70
210000003169 central nervous system Anatomy 0.000 claims description 55
239000003795 chemical substances by application Substances 0.000 claims description 52
108010040149 Junctional Adhesion Molecule B Proteins 0.000 claims description 51
241000282414 Homo sapiens Species 0.000 claims description 48
125000000539 amino acid group Chemical group 0.000 claims description 47
101001046633 Homo sapiens Junctional adhesion molecule A Proteins 0.000 claims description 45
102000045155 human F11R Human genes 0.000 claims description 45
238000006467 substitution reaction Methods 0.000 claims description 43
108090000467 Interferon-beta Proteins 0.000 claims description 41
102000003996 Interferon-beta Human genes 0.000 claims description 41
229960001388 interferon-beta Drugs 0.000 claims description 41
-1 glycerol ester Chemical class 0.000 claims description 40
241000894007 species Species 0.000 claims description 38
101001050321 Homo sapiens Junctional adhesion molecule C Proteins 0.000 claims description 36
210000001175 cerebrospinal fluid Anatomy 0.000 claims description 34
239000003814 drug Substances 0.000 claims description 34
239000003623 enhancer Substances 0.000 claims description 33
230000035772 mutation Effects 0.000 claims description 33
230000032258 transport Effects 0.000 claims description 31
210000001519 tissue Anatomy 0.000 claims description 27
239000003112 inhibitor Substances 0.000 claims description 25
210000004379 membrane Anatomy 0.000 claims description 25
239000012528 membrane Substances 0.000 claims description 25
150000003839 salts Chemical class 0.000 claims description 25
238000009472 formulation Methods 0.000 claims description 23
238000011282 treatment Methods 0.000 claims description 22
101001086785 Homo sapiens Occludin Proteins 0.000 claims description 21
238000012217 deletion Methods 0.000 claims description 21
230000037430 deletion Effects 0.000 claims description 21
230000006870 function Effects 0.000 claims description 21
102000044785 human OCLN Human genes 0.000 claims description 21
239000003961 penetration enhancing agent Substances 0.000 claims description 21
229910052720 vanadium Inorganic materials 0.000 claims description 21
101001050320 Homo sapiens Junctional adhesion molecule B Proteins 0.000 claims description 20
239000002253 acid Substances 0.000 claims description 19
102000044193 human JAM3 Human genes 0.000 claims description 18
239000000126 substance Substances 0.000 claims description 18
102000004190 Enzymes Human genes 0.000 claims description 17
108090000790 Enzymes Proteins 0.000 claims description 17
241001529936 Murinae Species 0.000 claims description 17
229940088598 enzyme Drugs 0.000 claims description 17
102000046847 human JAM2 Human genes 0.000 claims description 17
238000010255 intramuscular injection Methods 0.000 claims description 16
239000007927 intramuscular injection Substances 0.000 claims description 16
230000001965 increasing effect Effects 0.000 claims description 15
238000003780 insertion Methods 0.000 claims description 15
230000037431 insertion Effects 0.000 claims description 15
229940124549 vasodilator Drugs 0.000 claims description 15
239000003071 vasodilator agent Substances 0.000 claims description 15
102400000739 Corticotropin Human genes 0.000 claims description 14
101800000414 Corticotropin Proteins 0.000 claims description 14
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 14
IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 claims description 14
229960000258 corticotropin Drugs 0.000 claims description 14
239000003981 vehicle Substances 0.000 claims description 14
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
239000012530 fluid Substances 0.000 claims description 13
201000010099 disease Diseases 0.000 claims description 12
230000036470 plasma concentration Effects 0.000 claims description 12
229940124597 therapeutic agent Drugs 0.000 claims description 12
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 11
102000055006 Calcitonin Human genes 0.000 claims description 11
108060001064 Calcitonin Proteins 0.000 claims description 11
229960004015 calcitonin Drugs 0.000 claims description 11
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 11
239000000275 Adrenocorticotropic Hormone Substances 0.000 claims description 10
239000004475 Arginine Substances 0.000 claims description 10
108700012941 GNRH1 Proteins 0.000 claims description 10
239000000579 Gonadotropin-Releasing Hormone Substances 0.000 claims description 10
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 10
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 10
102000009618 Transforming Growth Factors Human genes 0.000 claims description 10
108010009583 Transforming Growth Factors Proteins 0.000 claims description 10
230000002776 aggregation Effects 0.000 claims description 10
238000004220 aggregation Methods 0.000 claims description 10
229960005486 vaccine Drugs 0.000 claims description 10
102000004127 Cytokines Human genes 0.000 claims description 9
108090000695 Cytokines Proteins 0.000 claims description 9
108090000445 Parathyroid hormone Proteins 0.000 claims description 9
102000003982 Parathyroid hormone Human genes 0.000 claims description 9
102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims description 9
108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims description 9
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 9
239000000262 estrogen Substances 0.000 claims description 9
229940011871 estrogen Drugs 0.000 claims description 9
239000000199 parathyroid hormone Substances 0.000 claims description 9
229960001319 parathyroid hormone Drugs 0.000 claims description 9
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
241000700159 Rattus Species 0.000 claims description 8
102000011923 Thyrotropin Human genes 0.000 claims description 8
108010061174 Thyrotropin Proteins 0.000 claims description 8
108090000373 Tissue Plasminogen Activator Proteins 0.000 claims description 8
102000003978 Tissue Plasminogen Activator Human genes 0.000 claims description 8
239000002260 anti-inflammatory agent Substances 0.000 claims description 8
229940121363 anti-inflammatory agent Drugs 0.000 claims description 8
210000004369 blood Anatomy 0.000 claims description 8
239000008280 blood Substances 0.000 claims description 8
239000002738 chelating agent Substances 0.000 claims description 8
230000001747 exhibiting effect Effects 0.000 claims description 8
230000002209 hydrophobic effect Effects 0.000 claims description 8
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 8
210000003097 mucus Anatomy 0.000 claims description 8
150000003904 phospholipids Chemical class 0.000 claims description 8
229960000187 tissue plasminogen activator Drugs 0.000 claims description 8
239000013598 vector Substances 0.000 claims description 8
WDJHALXBUFZDSR-UHFFFAOYSA-N Acetoacetic acid Natural products CC(=O)CC(O)=O WDJHALXBUFZDSR-UHFFFAOYSA-N 0.000 claims description 7
102000002572 Alpha-Globulins Human genes 0.000 claims description 7
108010068307 Alpha-Globulins Proteins 0.000 claims description 7
101001046631 Bos taurus Junctional adhesion molecule A Proteins 0.000 claims description 7
229940127328 Cholesterol Synthesis Inhibitors Drugs 0.000 claims description 7
229920000858 Cyclodextrin Polymers 0.000 claims description 7
102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 7
108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 7
102000002265 Human Growth Hormone Human genes 0.000 claims description 7
108010000521 Human Growth Hormone Proteins 0.000 claims description 7
239000000854 Human Growth Hormone Substances 0.000 claims description 7
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 7
102000019197 Superoxide Dismutase Human genes 0.000 claims description 7
108010012715 Superoxide dismutase Proteins 0.000 claims description 7
239000000654 additive Substances 0.000 claims description 7
230000000996 additive effect Effects 0.000 claims description 7
239000002220 antihypertensive agent Substances 0.000 claims description 7
229940030600 antihypertensive agent Drugs 0.000 claims description 7
WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 7
239000003833 bile salt Substances 0.000 claims description 7
230000000903 blocking effect Effects 0.000 claims description 7
230000000593 degrading effect Effects 0.000 claims description 7
WOWBFOBYOAGEEA-UHFFFAOYSA-N diafenthiuron Chemical compound CC(C)C1=C(NC(=S)NC(C)(C)C)C(C(C)C)=CC(OC=2C=CC=CC=2)=C1 WOWBFOBYOAGEEA-UHFFFAOYSA-N 0.000 claims description 7
150000002081 enamines Chemical class 0.000 claims description 7
239000002532 enzyme inhibitor Substances 0.000 claims description 7
229940125532 enzyme inhibitor Drugs 0.000 claims description 7
239000003172 expectorant agent Substances 0.000 claims description 7
230000004136 fatty acid synthesis Effects 0.000 claims description 7
229940126864 fibroblast growth factor Drugs 0.000 claims description 7
DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims description 7
229960000991 ketoprofen Drugs 0.000 claims description 7
239000002502 liposome Substances 0.000 claims description 7
150000004667 medium chain fatty acids Chemical class 0.000 claims description 7
239000000693 micelle Substances 0.000 claims description 7
239000003607 modifier Substances 0.000 claims description 7
229940066491 mucolytics Drugs 0.000 claims description 7
239000002840 nitric oxide donor Substances 0.000 claims description 7
150000003872 salicylic acid derivatives Chemical class 0.000 claims description 7
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 7
229940126586 small molecule drug Drugs 0.000 claims description 7
239000011734 sodium Substances 0.000 claims description 7
229910052708 sodium Inorganic materials 0.000 claims description 7
239000004094 surface-active agent Substances 0.000 claims description 7
108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 6
108010025020 Nerve Growth Factor Proteins 0.000 claims description 6
102000015336 Nerve Growth Factor Human genes 0.000 claims description 6
239000004365 Protease Substances 0.000 claims description 6
101001046630 Rattus norvegicus Junctional adhesion molecule A Proteins 0.000 claims description 6
102000013275 Somatomedins Human genes 0.000 claims description 6
108090000631 Trypsin Proteins 0.000 claims description 6
102000004142 Trypsin Human genes 0.000 claims description 6
230000002378 acidificating effect Effects 0.000 claims description 6
239000003242 anti bacterial agent Substances 0.000 claims description 6
210000004081 cilia Anatomy 0.000 claims description 6
238000011260 co-administration Methods 0.000 claims description 6
239000003136 dopamine receptor stimulating agent Substances 0.000 claims description 6
229940088597 hormone Drugs 0.000 claims description 6
239000005556 hormone Substances 0.000 claims description 6
229940053128 nerve growth factor Drugs 0.000 claims description 6
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 6
239000012588 trypsin Substances 0.000 claims description 6
108010024976 Asparaginase Proteins 0.000 claims description 5
102000015790 Asparaginase Human genes 0.000 claims description 5
108010049140 Endorphins Proteins 0.000 claims description 5
102000009025 Endorphins Human genes 0.000 claims description 5
102000003951 Erythropoietin Human genes 0.000 claims description 5
108090000394 Erythropoietin Proteins 0.000 claims description 5
102000003886 Glycoproteins Human genes 0.000 claims description 5
108090000288 Glycoproteins Proteins 0.000 claims description 5
102400000050 Oxytocin Human genes 0.000 claims description 5
101800000989 Oxytocin Proteins 0.000 claims description 5
XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 claims description 5
108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 5
108010003205 Vasoactive Intestinal Peptide Proteins 0.000 claims description 5
102400000015 Vasoactive intestinal peptide Human genes 0.000 claims description 5
239000003098 androgen Substances 0.000 claims description 5
239000000730 antalgic agent Substances 0.000 claims description 5
239000000043 antiallergic agent Substances 0.000 claims description 5
239000003416 antiarrhythmic agent Substances 0.000 claims description 5
239000000935 antidepressant agent Substances 0.000 claims description 5
239000002246 antineoplastic agent Substances 0.000 claims description 5
239000003443 antiviral agent Substances 0.000 claims description 5
229960003272 asparaginase Drugs 0.000 claims description 5
DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 claims description 5
230000001580 bacterial effect Effects 0.000 claims description 5
108700021293 carbetocin Proteins 0.000 claims description 5
229960001118 carbetocin Drugs 0.000 claims description 5
NSTRIRCPWQHTIA-DTRKZRJBSA-N carbetocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSCCCC(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(OC)C=C1 NSTRIRCPWQHTIA-DTRKZRJBSA-N 0.000 claims description 5
CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 claims description 5
229960001380 cimetidine Drugs 0.000 claims description 5
229940105423 erythropoietin Drugs 0.000 claims description 5
VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 claims description 5
229940005483 opioid analgesics Drugs 0.000 claims description 5
230000003204 osmotic effect Effects 0.000 claims description 5
XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 claims description 5
229960001723 oxytocin Drugs 0.000 claims description 5
229960003604 testosterone Drugs 0.000 claims description 5
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 5
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 4
229930000680 A04AD01 - Scopolamine Natural products 0.000 claims description 4
102000009027 Albumins Human genes 0.000 claims description 4
102000006734 Beta-Globulins Human genes 0.000 claims description 4
108010087504 Beta-Globulins Proteins 0.000 claims description 4
108010051479 Bombesin Proteins 0.000 claims description 4
102000013585 Bombesin Human genes 0.000 claims description 4
108010075016 Ceruloplasmin Proteins 0.000 claims description 4
102100023321 Ceruloplasmin Human genes 0.000 claims description 4
OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 claims description 4
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 4
108010036949 Cyclosporine Proteins 0.000 claims description 4
229940098778 Dopamine receptor agonist Drugs 0.000 claims description 4
108010092674 Enkephalins Proteins 0.000 claims description 4
102000008946 Fibrinogen Human genes 0.000 claims description 4
108010049003 Fibrinogen Proteins 0.000 claims description 4
102000012673 Follicle Stimulating Hormone Human genes 0.000 claims description 4
108010079345 Follicle Stimulating Hormone Proteins 0.000 claims description 4
108060003199 Glucagon Proteins 0.000 claims description 4
102400000321 Glucagon Human genes 0.000 claims description 4
102400000932 Gonadoliberin-1 Human genes 0.000 claims description 4
102000006771 Gonadotropins Human genes 0.000 claims description 4
108010086677 Gonadotropins Proteins 0.000 claims description 4
102000000543 Histamine Receptors Human genes 0.000 claims description 4
108010002059 Histamine Receptors Proteins 0.000 claims description 4
101500026183 Homo sapiens Gonadoliberin-1 Proteins 0.000 claims description 4
STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 claims description 4
102000004877 Insulin Human genes 0.000 claims description 4
108090001061 Insulin Proteins 0.000 claims description 4
102000007330 LDL Lipoproteins Human genes 0.000 claims description 4
108010007622 LDL Lipoproteins Proteins 0.000 claims description 4
URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 claims description 4
NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 4
108010007859 Lisinopril Proteins 0.000 claims description 4
101800001751 Melanocyte-stimulating hormone alpha Proteins 0.000 claims description 4
STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 claims description 4
108090000526 Papain Proteins 0.000 claims description 4
108010071690 Prealbumin Proteins 0.000 claims description 4
102100027467 Pro-opiomelanocortin Human genes 0.000 claims description 4
108010057464 Prolactin Proteins 0.000 claims description 4
102000003946 Prolactin Human genes 0.000 claims description 4
102100027378 Prothrombin Human genes 0.000 claims description 4
108010094028 Prothrombin Proteins 0.000 claims description 4
GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims description 4
102000004338 Transferrin Human genes 0.000 claims description 4
108090000901 Transferrin Proteins 0.000 claims description 4
102400001320 Transforming growth factor alpha Human genes 0.000 claims description 4
101800004564 Transforming growth factor alpha Proteins 0.000 claims description 4
GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 claims description 4
108010004977 Vasopressins Proteins 0.000 claims description 4
102000002852 Vasopressins Human genes 0.000 claims description 4
230000000954 anitussive effect Effects 0.000 claims description 4
230000001387 anti-histamine Effects 0.000 claims description 4
229940088710 antibiotic agent Drugs 0.000 claims description 4
239000003529 anticholesteremic agent Substances 0.000 claims description 4
229940127226 anticholesterol agent Drugs 0.000 claims description 4
229940125682 antidementia agent Drugs 0.000 claims description 4
229940121375 antifungal agent Drugs 0.000 claims description 4
239000000739 antihistaminic agent Substances 0.000 claims description 4
229960005475 antiinfective agent Drugs 0.000 claims description 4
239000004599 antimicrobial Substances 0.000 claims description 4
239000003963 antioxidant agent Substances 0.000 claims description 4
239000000074 antisense oligonucleotide Substances 0.000 claims description 4
238000012230 antisense oligonucleotides Methods 0.000 claims description 4
229940124584 antitussives Drugs 0.000 claims description 4
239000003699 antiulcer agent Substances 0.000 claims description 4
KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 claims description 4
230000006793 arrhythmia Effects 0.000 claims description 4
206010003119 arrhythmia Diseases 0.000 claims description 4
239000012867 bioactive agent Substances 0.000 claims description 4
QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 claims description 4
229960002495 buspirone Drugs 0.000 claims description 4
FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims description 4
229960000830 captopril Drugs 0.000 claims description 4
239000000496 cardiotonic agent Substances 0.000 claims description 4
SCKYRAXSEDYPSA-UHFFFAOYSA-N ciclopirox Chemical compound ON1C(=O)C=C(C)C=C1C1CCCCC1 SCKYRAXSEDYPSA-UHFFFAOYSA-N 0.000 claims description 4
229960001265 ciclosporin Drugs 0.000 claims description 4
OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 claims description 4
229960000265 cromoglicic acid Drugs 0.000 claims description 4
229930182912 cyclosporin Natural products 0.000 claims description 4
WOUOLAUOZXOLJQ-MBSDFSHPSA-N delapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N(CC(O)=O)C1CC2=CC=CC=C2C1)CC1=CC=CC=C1 WOUOLAUOZXOLJQ-MBSDFSHPSA-N 0.000 claims description 4
229960005227 delapril Drugs 0.000 claims description 4
VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 claims description 4
XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 claims description 4
229960001596 famotidine Drugs 0.000 claims description 4
108060002885 fetuin Proteins 0.000 claims description 4
102000013361 fetuin Human genes 0.000 claims description 4
229940012952 fibrinogen Drugs 0.000 claims description 4
229940028334 follicle stimulating hormone Drugs 0.000 claims description 4
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims description 4
229960004666 glucagon Drugs 0.000 claims description 4
XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 claims description 4
229960001442 gonadorelin Drugs 0.000 claims description 4
239000002622 gonadotropin Substances 0.000 claims description 4
230000002267 hypothalamic effect Effects 0.000 claims description 4
229940125396 insulin Drugs 0.000 claims description 4
229960004194 lidocaine Drugs 0.000 claims description 4
RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 claims description 4
229960002394 lisinopril Drugs 0.000 claims description 4
CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 claims description 4
DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 claims description 4
229960003793 midazolam Drugs 0.000 claims description 4
239000003158 myorelaxant agent Substances 0.000 claims description 4
239000002664 nootropic agent Substances 0.000 claims description 4
229950004864 olamine Drugs 0.000 claims description 4
235000019834 papain Nutrition 0.000 claims description 4
229940055729 papain Drugs 0.000 claims description 4
229960003387 progesterone Drugs 0.000 claims description 4
239000000583 progesterone congener Substances 0.000 claims description 4
229940097325 prolactin Drugs 0.000 claims description 4
229940039716 prothrombin Drugs 0.000 claims description 4
239000004089 psychotropic agent Substances 0.000 claims description 4
VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 claims description 4
229960000620 ranitidine Drugs 0.000 claims description 4
STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 claims description 4
229960002646 scopolamine Drugs 0.000 claims description 4
239000012581 transferrin Substances 0.000 claims description 4
229960003726 vasopressin Drugs 0.000 claims description 4
239000013603 viral vector Substances 0.000 claims description 4
WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 claims description 4
XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 claims description 3
102000055025 Adenosine deaminases Human genes 0.000 claims description 3
108700040115 Adenosine deaminases Proteins 0.000 claims description 3
108020000948 Antisense Oligonucleotides Proteins 0.000 claims description 3
102000004452 Arginase Human genes 0.000 claims description 3
108700024123 Arginases Proteins 0.000 claims description 3
102000006395 Globulins Human genes 0.000 claims description 3
108010044091 Globulins Proteins 0.000 claims description 3
102000018997 Growth Hormone Human genes 0.000 claims description 3
108010051696 Growth Hormone Proteins 0.000 claims description 3
102000015779 HDL Lipoproteins Human genes 0.000 claims description 3
108010010234 HDL Lipoproteins Proteins 0.000 claims description 3
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 3
108010047761 Interferon-alpha Proteins 0.000 claims description 3
102000006992 Interferon-alpha Human genes 0.000 claims description 3
108020001621 Natriuretic Peptide Proteins 0.000 claims description 3
102000004571 Natriuretic peptide Human genes 0.000 claims description 3
108010083644 Ribonucleases Proteins 0.000 claims description 3
102000006382 Ribonucleases Human genes 0.000 claims description 3
201000001880 Sexual dysfunction Diseases 0.000 claims description 3
239000000853 adhesive Substances 0.000 claims description 3
230000001070 adhesive effect Effects 0.000 claims description 3
230000003262 anti-osteoporosis Effects 0.000 claims description 3
239000003146 anticoagulant agent Substances 0.000 claims description 3
229940005513 antidepressants Drugs 0.000 claims description 3
239000003472 antidiabetic agent Substances 0.000 claims description 3
229940125708 antidiabetic agent Drugs 0.000 claims description 3
239000003429 antifungal agent Substances 0.000 claims description 3
239000002221 antipyretic Substances 0.000 claims description 3
229940125716 antipyretic agent Drugs 0.000 claims description 3
VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical group C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 claims description 3
229960004046 apomorphine Drugs 0.000 claims description 3
239000012830 cancer therapeutic Substances 0.000 claims description 3
229960002897 heparin Drugs 0.000 claims description 3
229920000669 heparin Polymers 0.000 claims description 3
229940052404 nasal powder Drugs 0.000 claims description 3
229940097496 nasal spray Drugs 0.000 claims description 3
239000007922 nasal spray Substances 0.000 claims description 3
239000000692 natriuretic peptide Substances 0.000 claims description 3
FATBGEAMYMYZAF-KTKRTIGZSA-N oleamide Chemical compound CCCCCCCC\C=C/CCCCCCCC(N)=O FATBGEAMYMYZAF-KTKRTIGZSA-N 0.000 claims description 3
FATBGEAMYMYZAF-UHFFFAOYSA-N oleicacidamide-heptaglycolether Natural products CCCCCCCCC=CCCCCCCCC(N)=O FATBGEAMYMYZAF-UHFFFAOYSA-N 0.000 claims description 3
239000003401 opiate antagonist Substances 0.000 claims description 3
239000000843 powder Substances 0.000 claims description 3
239000000186 progesterone Substances 0.000 claims description 3
231100000872 sexual dysfunction Toxicity 0.000 claims description 3
230000004936 stimulating effect Effects 0.000 claims description 3
229960000195 terbutaline Drugs 0.000 claims description 3
108010088751 Albumins Proteins 0.000 claims description 2
208000010228 Erectile Dysfunction Diseases 0.000 claims description 2
206010057671 Female sexual dysfunction Diseases 0.000 claims description 2
108010090535 alpha-albumin Proteins 0.000 claims description 2
230000000844 anti-bacterial effect Effects 0.000 claims description 2
229940127219 anticoagulant drug Drugs 0.000 claims description 2
239000001961 anticonvulsive agent Substances 0.000 claims description 2
RMEDXOLNCUSCGS-UHFFFAOYSA-N droperidol Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CC=C(N2C(NC3=CC=CC=C32)=O)CC1 RMEDXOLNCUSCGS-UHFFFAOYSA-N 0.000 claims description 2
229960000394 droperidol Drugs 0.000 claims description 2
201000001881 impotence Diseases 0.000 claims description 2
230000008823 permeabilization Effects 0.000 claims description 2
108010040082 Junctional Adhesion Molecule A Proteins 0.000 claims 17
102100022304 Junctional adhesion molecule A Human genes 0.000 claims 17
108090000371 Esterases Proteins 0.000 claims 2
102100029290 Transthyretin Human genes 0.000 claims 2
OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 claims 2
229960004373 acetylcholine Drugs 0.000 claims 2
DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 claims 2
PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 claims 2
102000003390 tumor necrosis factor Human genes 0.000 claims 2
241000894006 Bacteria Species 0.000 claims 1
108091034117 Oligonucleotide Proteins 0.000 claims 1
230000001430 anti-depressive effect Effects 0.000 claims 1
230000003556 anti-epileptic effect Effects 0.000 claims 1
229940127090 anticoagulant agent Drugs 0.000 claims 1
229960003965 antiepileptics Drugs 0.000 claims 1
230000003078 antioxidant effect Effects 0.000 claims 1
229960003749 ciclopirox Drugs 0.000 claims 1
230000000994 depressogenic effect Effects 0.000 claims 1
230000002710 gonadal effect Effects 0.000 claims 1
230000002401 inhibitory effect Effects 0.000 claims 1
AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 claims 1
230000035515 penetration Effects 0.000 claims 1
IOUVKUPGCMBWBT-QNDFHXLGSA-N phlorizin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 IOUVKUPGCMBWBT-QNDFHXLGSA-N 0.000 claims 1
230000001105 regulatory effect Effects 0.000 claims 1
GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical compound C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 claims 1
229960004739 sufentanil Drugs 0.000 claims 1
230000000694 effects Effects 0.000 abstract description 32
239000000816 peptidomimetic Substances 0.000 abstract description 31
210000002919 epithelial cell Anatomy 0.000 abstract description 20
239000008191 permeabilizing agent Substances 0.000 abstract description 9
230000005764 inhibitory process Effects 0.000 abstract description 3
MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 280
235000018102 proteins Nutrition 0.000 description 252
235000001014 amino acid Nutrition 0.000 description 151
230000000875 corresponding effect Effects 0.000 description 55
210000004027 cell Anatomy 0.000 description 37
102100023430 Junctional adhesion molecule B Human genes 0.000 description 34
210000002966 serum Anatomy 0.000 description 25
229920001184 polypeptide Polymers 0.000 description 22
210000001578 tight junction Anatomy 0.000 description 21
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
230000004071 biological effect Effects 0.000 description 18
150000001408 amides Chemical class 0.000 description 17
238000006243 chemical reaction Methods 0.000 description 17
229940079593 drug Drugs 0.000 description 17
230000004927 fusion Effects 0.000 description 17
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 15
BMQYVXCPAOLZOK-UHFFFAOYSA-N Trihydroxypropylpterisin Natural products OCC(O)C(O)C1=CN=C2NC(N)=NC(=O)C2=N1 BMQYVXCPAOLZOK-UHFFFAOYSA-N 0.000 description 14
239000012634 fragment Substances 0.000 description 14
230000003993 interaction Effects 0.000 description 14
BMQYVXCPAOLZOK-XINAWCOVSA-N neopterin Chemical compound OC[C@@H](O)[C@@H](O)C1=CN=C2NC(N)=NC(=O)C2=N1 BMQYVXCPAOLZOK-XINAWCOVSA-N 0.000 description 14
239000003446 ligand Substances 0.000 description 13
230000004048 modification Effects 0.000 description 13
238000012986 modification Methods 0.000 description 13
125000000217 alkyl group Chemical group 0.000 description 12
102000005962 receptors Human genes 0.000 description 12
108020003175 receptors Proteins 0.000 description 12
230000015572 biosynthetic process Effects 0.000 description 11
210000004899 c-terminal region Anatomy 0.000 description 11
150000002148 esters Chemical class 0.000 description 11
238000001727 in vivo Methods 0.000 description 11
210000000265 leukocyte Anatomy 0.000 description 11
102100025255 Haptoglobin Human genes 0.000 description 10
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 10
238000007792 addition Methods 0.000 description 10
125000003277 amino group Chemical group 0.000 description 10
102000015736 beta 2-Microglobulin Human genes 0.000 description 10
108010081355 beta 2-Microglobulin Proteins 0.000 description 10
108091036078 conserved sequence Proteins 0.000 description 10
230000035699 permeability Effects 0.000 description 10
108010027843 zonulin Proteins 0.000 description 10
230000004888 barrier function Effects 0.000 description 9
230000004887 epithelial permeability Effects 0.000 description 9
238000002347 injection Methods 0.000 description 9
239000007924 injection Substances 0.000 description 9
230000000149 penetrating effect Effects 0.000 description 9
230000008901 benefit Effects 0.000 description 8
230000007423 decrease Effects 0.000 description 8
239000000539 dimer Substances 0.000 description 8
239000003550 marker Substances 0.000 description 8
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 8
108090000580 Claudin-2 Proteins 0.000 description 7
102000004056 Claudin-2 Human genes 0.000 description 7
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 7
150000001720 carbohydrates Chemical group 0.000 description 7
102000003899 claudin 8 Human genes 0.000 description 7
108090000239 claudin 8 Proteins 0.000 description 7
230000001086 cytosolic effect Effects 0.000 description 7
210000002889 endothelial cell Anatomy 0.000 description 7
230000002163 immunogen Effects 0.000 description 7
239000003701 inert diluent Substances 0.000 description 7
150000002632 lipids Chemical class 0.000 description 7
108091005601 modified peptides Proteins 0.000 description 7
102000004162 Claudin-1 Human genes 0.000 description 6
108090000600 Claudin-1 Proteins 0.000 description 6
101000749331 Homo sapiens Claudin-1 Proteins 0.000 description 6
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
102000007079 Peptide Fragments Human genes 0.000 description 6
108010033276 Peptide Fragments Proteins 0.000 description 6
102000000591 Tight Junction Proteins Human genes 0.000 description 6
108010002321 Tight Junction Proteins Proteins 0.000 description 6
238000003556 assay Methods 0.000 description 6
210000000170 cell membrane Anatomy 0.000 description 6
239000002299 complementary DNA Substances 0.000 description 6
102000049940 human CLDN1 Human genes 0.000 description 6
238000000338 in vitro Methods 0.000 description 6
229920002521 macromolecule Polymers 0.000 description 6
230000001404 mediated effect Effects 0.000 description 6
230000004677 mucosal permeability Effects 0.000 description 6
230000036961 partial effect Effects 0.000 description 6
KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical group O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 6
150000003512 tertiary amines Chemical class 0.000 description 6
XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
102000004161 Claudin-4 Human genes 0.000 description 5
108090000601 Claudin-4 Proteins 0.000 description 5
102000003859 Claudin-6 Human genes 0.000 description 5
108090000229 Claudin-6 Proteins 0.000 description 5
239000003153 chemical reaction reagent Substances 0.000 description 5
102000004361 claudin 10 Human genes 0.000 description 5
108090000999 claudin 10 Proteins 0.000 description 5
239000000562 conjugate Substances 0.000 description 5
238000009510 drug design Methods 0.000 description 5
239000010410 layer Substances 0.000 description 5
238000004519 manufacturing process Methods 0.000 description 5
210000004400 mucous membrane Anatomy 0.000 description 5
150000007523 nucleic acids Chemical class 0.000 description 5
230000037361 pathway Effects 0.000 description 5
230000000069 prophylactic effect Effects 0.000 description 5
230000002829 reductive effect Effects 0.000 description 5
238000003786 synthesis reaction Methods 0.000 description 5
102000004106 Claudin-3 Human genes 0.000 description 4
108090000599 Claudin-3 Proteins 0.000 description 4
102000002045 Endothelin Human genes 0.000 description 4
108050009340 Endothelin Proteins 0.000 description 4
101000882901 Homo sapiens Claudin-2 Proteins 0.000 description 4
101000882908 Homo sapiens Claudin-3 Proteins 0.000 description 4
101000882890 Homo sapiens Claudin-4 Proteins 0.000 description 4
101000882896 Homo sapiens Claudin-5 Proteins 0.000 description 4
102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
239000004472 Lysine Substances 0.000 description 4
108091028043 Nucleic acid sequence Proteins 0.000 description 4
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
241000700605 Viruses Species 0.000 description 4
235000014633 carbohydrates Nutrition 0.000 description 4
230000021615 conjugation Effects 0.000 description 4
238000007796 conventional method Methods 0.000 description 4
210000005220 cytoplasmic tail Anatomy 0.000 description 4
238000006471 dimerization reaction Methods 0.000 description 4
ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 4
230000004890 epithelial barrier function Effects 0.000 description 4
210000000981 epithelium Anatomy 0.000 description 4
210000002950 fibroblast Anatomy 0.000 description 4
230000013595 glycosylation Effects 0.000 description 4
238000006206 glycosylation reaction Methods 0.000 description 4
239000003102 growth factor Substances 0.000 description 4
102000047718 human CLDN2 Human genes 0.000 description 4
102000050015 human CLDN3 Human genes 0.000 description 4
102000050035 human CLDN4 Human genes 0.000 description 4
102000047772 human CLDN5 Human genes 0.000 description 4
230000007062 hydrolysis Effects 0.000 description 4
238000006460 hydrolysis reaction Methods 0.000 description 4
235000018977 lysine Nutrition 0.000 description 4
230000004682 mucosal barrier function Effects 0.000 description 4
210000002850 nasal mucosa Anatomy 0.000 description 4
238000010647 peptide synthesis reaction Methods 0.000 description 4
229920000642 polymer Polymers 0.000 description 4
239000000047 product Substances 0.000 description 4
239000007787 solid Substances 0.000 description 4
229940124530 sulfonamide Drugs 0.000 description 4
150000003456 sulfonamides Chemical class 0.000 description 4
235000001508 sulfur Nutrition 0.000 description 4
208000024891 symptom Diseases 0.000 description 4
238000011191 terminal modification Methods 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
241000283690 Bos taurus Species 0.000 description 3
KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 3
102000004057 Claudin-5 Human genes 0.000 description 3
108090000582 Claudin-5 Proteins 0.000 description 3
KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 3
101000912652 Homo sapiens Claudin-7 Proteins 0.000 description 3
101000912661 Homo sapiens Claudin-9 Proteins 0.000 description 3
206010061218 Inflammation Diseases 0.000 description 3
102000015696 Interleukins Human genes 0.000 description 3
108010063738 Interleukins Proteins 0.000 description 3
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
108010052285 Membrane Proteins Proteins 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
241000607626 Vibrio cholerae Species 0.000 description 3
230000002411 adverse Effects 0.000 description 3
125000003545 alkoxy group Chemical group 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
125000003118 aryl group Chemical group 0.000 description 3
210000004082 barrier epithelial cell Anatomy 0.000 description 3
239000002585 base Substances 0.000 description 3
230000000295 complement effect Effects 0.000 description 3
239000013078 crystal Substances 0.000 description 3
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
230000006378 damage Effects 0.000 description 3
238000013461 design Methods 0.000 description 3
238000009792 diffusion process Methods 0.000 description 3
210000005225 erectile tissue Anatomy 0.000 description 3
239000010408 film Substances 0.000 description 3
125000000524 functional group Chemical group 0.000 description 3
230000014509 gene expression Effects 0.000 description 3
235000011187 glycerol Nutrition 0.000 description 3
150000004820 halides Chemical class 0.000 description 3
125000000623 heterocyclic group Chemical group 0.000 description 3
102000052788 human CLDN7 Human genes 0.000 description 3
102000044350 human CLDN9 Human genes 0.000 description 3
238000009396 hybridization Methods 0.000 description 3
229910000040 hydrogen fluoride Inorganic materials 0.000 description 3
125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
230000004054 inflammatory process Effects 0.000 description 3
229940047122 interleukins Drugs 0.000 description 3
229960000310 isoleucine Drugs 0.000 description 3
210000003734 kidney Anatomy 0.000 description 3
238000002372 labelling Methods 0.000 description 3
230000005012 migration Effects 0.000 description 3
238000013508 migration Methods 0.000 description 3
108091005573 modified proteins Proteins 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
230000000144 pharmacologic effect Effects 0.000 description 3
238000012545 processing Methods 0.000 description 3
238000000746 purification Methods 0.000 description 3
230000009467 reduction Effects 0.000 description 3
229920005989 resin Polymers 0.000 description 3
239000011347 resin Substances 0.000 description 3
230000004044 response Effects 0.000 description 3
239000000523 sample Substances 0.000 description 3
150000003335 secondary amines Chemical class 0.000 description 3
230000035945 sensitivity Effects 0.000 description 3
238000002864 sequence alignment Methods 0.000 description 3
230000001568 sexual effect Effects 0.000 description 3
239000000243 solution Substances 0.000 description 3
230000000638 stimulation Effects 0.000 description 3
238000007920 subcutaneous administration Methods 0.000 description 3
125000001424 substituent group Chemical group 0.000 description 3
229910052717 sulfur Inorganic materials 0.000 description 3
239000011593 sulfur Substances 0.000 description 3
230000001839 systemic circulation Effects 0.000 description 3
238000012360 testing method Methods 0.000 description 3
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
239000004474 valine Substances 0.000 description 3
229940118696 vibrio cholerae Drugs 0.000 description 3
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
102000007445 2',5'-Oligoadenylate Synthetase Human genes 0.000 description 2
108010086241 2',5'-Oligoadenylate Synthetase Proteins 0.000 description 2
FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 2
QXZBMSIDSOZZHK-DOPDSADYSA-N 31362-50-2 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CNC=N1 QXZBMSIDSOZZHK-DOPDSADYSA-N 0.000 description 2
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
102400000344 Angiotensin-1 Human genes 0.000 description 2
101800000734 Angiotensin-1 Proteins 0.000 description 2
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 description 2
102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 description 2
102100040935 Claudin-20 Human genes 0.000 description 2
101710196871 Claudin-20 Proteins 0.000 description 2
108050007296 Claudin-7 Proteins 0.000 description 2
102000018156 Claudin-7 Human genes 0.000 description 2
108050007295 Claudin-9 Proteins 0.000 description 2
102000018157 Claudin-9 Human genes 0.000 description 2
239000004971 Cross linker Substances 0.000 description 2
102000001189 Cyclic Peptides Human genes 0.000 description 2
108010069514 Cyclic Peptides Proteins 0.000 description 2
150000008574 D-amino acids Chemical class 0.000 description 2
108020004414 DNA Proteins 0.000 description 2
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
108010016626 Dipeptides Proteins 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
102100021866 Hepatocyte growth factor Human genes 0.000 description 2
108010007267 Hirudins Proteins 0.000 description 2
102000007625 Hirudins Human genes 0.000 description 2
241000725303 Human immunodeficiency virus Species 0.000 description 2
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 2
206010020565 Hyperaemia Diseases 0.000 description 2
108060003951 Immunoglobulin Proteins 0.000 description 2
102000016844 Immunoglobulin-like domains Human genes 0.000 description 2
108050006430 Immunoglobulin-like domains Proteins 0.000 description 2
108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 2
102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 2
108010005716 Interferon beta-1a Proteins 0.000 description 2
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical group OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 2
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
102000018697 Membrane Proteins Human genes 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
101001050316 Mus musculus Junctional adhesion molecule C Proteins 0.000 description 2
230000004988 N-glycosylation Effects 0.000 description 2
108020004711 Nucleic Acid Probes Proteins 0.000 description 2
229930012538 Paclitaxel Natural products 0.000 description 2
102000035195 Peptidases Human genes 0.000 description 2
108091005804 Peptidases Proteins 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
102000007584 Prealbumin Human genes 0.000 description 2
241000725643 Respiratory syncytial virus Species 0.000 description 2
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
239000004473 Threonine Substances 0.000 description 2
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
230000021736 acetylation Effects 0.000 description 2
238000006640 acetylation reaction Methods 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
230000009471 action Effects 0.000 description 2
230000004913 activation Effects 0.000 description 2
239000012190 activator Substances 0.000 description 2
125000001931 aliphatic group Chemical group 0.000 description 2
230000029936 alkylation Effects 0.000 description 2
238000005804 alkylation reaction Methods 0.000 description 2
125000003368 amide group Chemical group 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
229940030486 androgens Drugs 0.000 description 2
ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 2
239000003434 antitussive agent Substances 0.000 description 2
238000013459 approach Methods 0.000 description 2
229960001230 asparagine Drugs 0.000 description 2
235000009582 asparagine Nutrition 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 2
210000000988 bone and bone Anatomy 0.000 description 2
239000011575 calcium Substances 0.000 description 2
238000004422 calculation algorithm Methods 0.000 description 2
239000004202 carbamide Substances 0.000 description 2
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
210000000748 cardiovascular system Anatomy 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
108010015046 cell aggregation factors Proteins 0.000 description 2
230000017455 cell-cell adhesion Effects 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
238000010276 construction Methods 0.000 description 2
230000002596 correlated effect Effects 0.000 description 2
238000004132 cross linking Methods 0.000 description 2
125000004122 cyclic group Chemical group 0.000 description 2
235000018417 cysteine Nutrition 0.000 description 2
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000001212 derivatisation Methods 0.000 description 2
PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
238000001647 drug administration Methods 0.000 description 2
239000003792 electrolyte Substances 0.000 description 2
210000003038 endothelium Anatomy 0.000 description 2
210000001723 extracellular space Anatomy 0.000 description 2
210000005095 gastrointestinal system Anatomy 0.000 description 2
239000000499 gel Substances 0.000 description 2
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 2
229940006607 hirudin Drugs 0.000 description 2
WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 2
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
229960002591 hydroxyproline Drugs 0.000 description 2
210000002865 immune cell Anatomy 0.000 description 2
230000028993 immune response Effects 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
102000018358 immunoglobulin Human genes 0.000 description 2
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
229960004461 interferon beta-1a Drugs 0.000 description 2
230000000968 intestinal effect Effects 0.000 description 2
230000003870 intestinal permeability Effects 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
108010046018 leukocyte inhibitory factor Proteins 0.000 description 2
230000004807 localization Effects 0.000 description 2
FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 2
238000005259 measurement Methods 0.000 description 2
GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
229930182817 methionine Natural products 0.000 description 2
238000010369 molecular cloning Methods 0.000 description 2
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
210000005036 nerve Anatomy 0.000 description 2
230000001537 neural effect Effects 0.000 description 2
210000001331 nose Anatomy 0.000 description 2
239000002853 nucleic acid probe Substances 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
230000003647 oxidation Effects 0.000 description 2
238000007254 oxidation reaction Methods 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
229960001592 paclitaxel Drugs 0.000 description 2
XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 2
239000000813 peptide hormone Substances 0.000 description 2
125000001151 peptidyl group Chemical group 0.000 description 2
210000005259 peripheral blood Anatomy 0.000 description 2
239000011886 peripheral blood Substances 0.000 description 2
210000001428 peripheral nervous system Anatomy 0.000 description 2
238000002823 phage display Methods 0.000 description 2
239000008177 pharmaceutical agent Substances 0.000 description 2
230000026731 phosphorylation Effects 0.000 description 2
238000006366 phosphorylation reaction Methods 0.000 description 2
BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 2
230000001766 physiological effect Effects 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
239000004033 plastic Substances 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
238000006116 polymerization reaction Methods 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
230000002265 prevention Effects 0.000 description 2
230000017854 proteolysis Effects 0.000 description 2
LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 2
238000001525 receptor binding assay Methods 0.000 description 2
238000011084 recovery Methods 0.000 description 2
230000007017 scission Effects 0.000 description 2
238000012216 screening Methods 0.000 description 2
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
230000035946 sexual desire Effects 0.000 description 2
239000002356 single layer Substances 0.000 description 2
150000003384 small molecules Chemical class 0.000 description 2
238000001179 sorption measurement Methods 0.000 description 2
238000010254 subcutaneous injection Methods 0.000 description 2
239000007929 subcutaneous injection Substances 0.000 description 2
229940014800 succinic anhydride Drugs 0.000 description 2
229960002317 succinimide Drugs 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
230000008685 targeting Effects 0.000 description 2
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
201000008827 tuberculosis Diseases 0.000 description 2
238000005406 washing Methods 0.000 description 2
XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
SBKVPJHMSUXZTA-MEJXFZFPSA-N (2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-5-amino-2-[[2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]-4-methylsulfanylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoic acid Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 SBKVPJHMSUXZTA-MEJXFZFPSA-N 0.000 description 1
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
BEJKOYIMCGMNRB-GRHHLOCNSA-N (2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-amino-3-phenylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 BEJKOYIMCGMNRB-GRHHLOCNSA-N 0.000 description 1
CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 1
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
MGVRBUNKWISLAM-DQWUKECYSA-N (4s)-5-[[(2s)-1-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]-[(2s)-4-methyl-1-oxo-1-sulfooxypentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-[[(2s)-1-[(2s,3s)-2-[[(2s)-4-carboxy-2-[[(2s)-4-carboxy-2-[[(2s)-2-[[(2s)-3-carboxy-2-[[2-[[(2s)-2,4-diamino- Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N([C@@H](CC(C)C)C(=O)OS(O)(=O)=O)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC(N)=O)C1=CC=CC=C1 MGVRBUNKWISLAM-DQWUKECYSA-N 0.000 description 1
VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
WVXRAFOPTSTNLL-NKWVEPMBSA-N 2',3'-dideoxyadenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](CO)O1 WVXRAFOPTSTNLL-NKWVEPMBSA-N 0.000 description 1
SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
YQAXFVHNHSPUPO-RNJOBUHISA-N 2-[[(2s)-2-[[2-[[(2s,4r)-1-[(2s)-1-(2-aminoacetyl)pyrrolidine-2-carbonyl]-4-hydroxypyrrolidine-2-carbonyl]amino]acetyl]amino]propanoyl]amino]acetic acid Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@H]1N(C(=O)CN)CCC1 YQAXFVHNHSPUPO-RNJOBUHISA-N 0.000 description 1
DJQYYYCQOZMCRC-UHFFFAOYSA-N 2-aminopropane-1,3-dithiol Chemical group SCC(N)CS DJQYYYCQOZMCRC-UHFFFAOYSA-N 0.000 description 1
KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 1
238000005084 2D-nuclear magnetic resonance Methods 0.000 description 1
BRMWTNUJHUMWMS-UHFFFAOYSA-N 3-Methylhistidine Natural products CN1C=NC(CC(N)C(O)=O)=C1 BRMWTNUJHUMWMS-UHFFFAOYSA-N 0.000 description 1
LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 1
229940117976 5-hydroxylysine Drugs 0.000 description 1
229940000681 5-hydroxytryptophan Drugs 0.000 description 1
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
229930008281 A03AD01 - Papaverine Natural products 0.000 description 1
208000002874 Acne Vulgaris Diseases 0.000 description 1
102000007469 Actins Human genes 0.000 description 1
108010085238 Actins Proteins 0.000 description 1
102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
108700028369 Alleles Proteins 0.000 description 1
102000003730 Alpha-catenin Human genes 0.000 description 1
108090000020 Alpha-catenin Proteins 0.000 description 1
APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
QMMRCKSBBNJCMR-KMZPNFOHSA-N Angiotensin III Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCN=C(N)N)C(C)C)C1=CC=C(O)C=C1 QMMRCKSBBNJCMR-KMZPNFOHSA-N 0.000 description 1
102400000345 Angiotensin-2 Human genes 0.000 description 1
101800000733 Angiotensin-2 Proteins 0.000 description 1
102400000348 Angiotensin-3 Human genes 0.000 description 1
101800000738 Angiotensin-3 Proteins 0.000 description 1
102000004411 Antithrombin III Human genes 0.000 description 1
108090000935 Antithrombin III Proteins 0.000 description 1
108010083590 Apoproteins Proteins 0.000 description 1
102000006410 Apoproteins Human genes 0.000 description 1
206010003210 Arteriosclerosis Diseases 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
108010006654 Bleomycin Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
206010006956 Calcium deficiency Diseases 0.000 description 1
KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
229930186147 Cephalosporin Natural products 0.000 description 1
108091006146 Channels Proteins 0.000 description 1
101710091342 Chemotactic peptide Proteins 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
102100033473 Cingulin Human genes 0.000 description 1
101710122611 Cingulin Proteins 0.000 description 1
102000018159 Claudin-11 Human genes 0.000 description 1
108050007280 Claudin-11 Proteins 0.000 description 1
102100039518 Claudin-12 Human genes 0.000 description 1
101710197000 Claudin-12 Proteins 0.000 description 1
101710197006 Claudin-13 Proteins 0.000 description 1
102000004359 Claudin-15 Human genes 0.000 description 1
108090000997 Claudin-15 Proteins 0.000 description 1
102100039586 Claudin-17 Human genes 0.000 description 1
101710196830 Claudin-17 Proteins 0.000 description 1
102000002038 Claudin-18 Human genes 0.000 description 1
108050009324 Claudin-18 Proteins 0.000 description 1
102100040838 Claudin-19 Human genes 0.000 description 1
101710196827 Claudin-19 Proteins 0.000 description 1
206010053567 Coagulopathies Diseases 0.000 description 1
208000015943 Coeliac disease Diseases 0.000 description 1
MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 description 1
108090000204 Dipeptidase 1 Proteins 0.000 description 1
102100031939 Erythropoietin Human genes 0.000 description 1
UUOUOERPONYGOS-CLCRDYEYSA-N Fluocinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3C[C@H](F)C2=C1 UUOUOERPONYGOS-CLCRDYEYSA-N 0.000 description 1
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
102400000921 Gastrin Human genes 0.000 description 1
108010052343 Gastrins Proteins 0.000 description 1
229930182566 Gentamicin Natural products 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
229930186217 Glycolipid Natural products 0.000 description 1
108010008488 Glycylglycine Proteins 0.000 description 1
UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 description 1
NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Natural products C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 1
102100034523 Histone H4 Human genes 0.000 description 1
108010033040 Histones Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
101100095718 Homo sapiens SH2D2A gene Proteins 0.000 description 1
102000003839 Human Proteins Human genes 0.000 description 1
108090000144 Human Proteins Proteins 0.000 description 1
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
102000000589 Interleukin-1 Human genes 0.000 description 1
108010002352 Interleukin-1 Proteins 0.000 description 1
102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 1
108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 1
108060005987 Kallikrein Proteins 0.000 description 1
102000001399 Kallikrein Human genes 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 description 1
108060001084 Luciferase Proteins 0.000 description 1
239000005089 Luciferase Substances 0.000 description 1
102000009151 Luteinizing Hormone Human genes 0.000 description 1
108010073521 Luteinizing Hormone Proteins 0.000 description 1
102000008072 Lymphokines Human genes 0.000 description 1
108010074338 Lymphokines Proteins 0.000 description 1
102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
206010057672 Male sexual dysfunction Diseases 0.000 description 1
108010038049 Mating Factor Proteins 0.000 description 1
241000712079 Measles morbillivirus Species 0.000 description 1
201000009906 Meningitis Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
102000013967 Monokines Human genes 0.000 description 1
108010050619 Monokines Proteins 0.000 description 1
206010065764 Mucosal infection Diseases 0.000 description 1
241000711386 Mumps virus Species 0.000 description 1
101001050319 Mus musculus Junctional adhesion molecule B Proteins 0.000 description 1
108010021466 Mutant Proteins Proteins 0.000 description 1
102000008300 Mutant Proteins Human genes 0.000 description 1
DTERQYGMUDWYAZ-ZETCQYMHSA-N N(6)-acetyl-L-lysine Chemical compound CC(=O)NCCCC[C@H]([NH3+])C([O-])=O DTERQYGMUDWYAZ-ZETCQYMHSA-N 0.000 description 1
NTNWOCRCBQPEKQ-YFKPBYRVSA-N N(omega)-methyl-L-arginine Chemical compound CN=C(N)NCCC[C@H](N)C(O)=O NTNWOCRCBQPEKQ-YFKPBYRVSA-N 0.000 description 1
JDHILDINMRGULE-LURJTMIESA-N N(pros)-methyl-L-histidine Chemical compound CN1C=NC=C1C[C@H](N)C(O)=O JDHILDINMRGULE-LURJTMIESA-N 0.000 description 1
JJIHLJJYMXLCOY-BYPYZUCNSA-N N-acetyl-L-serine Chemical compound CC(=O)N[C@@H](CO)C(O)=O JJIHLJJYMXLCOY-BYPYZUCNSA-N 0.000 description 1
PYUSHNKNPOHWEZ-YFKPBYRVSA-N N-formyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC=O PYUSHNKNPOHWEZ-YFKPBYRVSA-N 0.000 description 1
WJBLNOPPDWQMCH-MBPVOVBZSA-N Nalmefene Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=C)O)CC1)O)CC1CC1 WJBLNOPPDWQMCH-MBPVOVBZSA-N 0.000 description 1
DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
102400001103 Neurotensin Human genes 0.000 description 1
101800001814 Neurotensin Proteins 0.000 description 1
SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
239000000006 Nitroglycerin Substances 0.000 description 1
238000000636 Northern blotting Methods 0.000 description 1
BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 1
108010093625 Opioid Peptides Proteins 0.000 description 1
102000001490 Opioid Peptides Human genes 0.000 description 1
102000004067 Osteocalcin Human genes 0.000 description 1
108090000573 Osteocalcin Proteins 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
102400000076 Osteostatin Human genes 0.000 description 1
UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 description 1
108010067372 Pancreatic elastase Proteins 0.000 description 1
102000016387 Pancreatic elastase Human genes 0.000 description 1
208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
208000037273 Pathologic Processes Diseases 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
108010067902 Peptide Library Proteins 0.000 description 1
ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
108091000080 Phosphotransferase Proteins 0.000 description 1
IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
108010093965 Polymyxin B Proteins 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
102000003923 Protein Kinase C Human genes 0.000 description 1
108090000315 Protein Kinase C Proteins 0.000 description 1
208000008425 Protein deficiency Diseases 0.000 description 1
241000589516 Pseudomonas Species 0.000 description 1
101100408135 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) phnA gene Proteins 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
108090000783 Renin Proteins 0.000 description 1
102100028255 Renin Human genes 0.000 description 1
IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
241000710799 Rubella virus Species 0.000 description 1
102100031779 SH2 domain-containing protein 2A Human genes 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
108010086019 Secretin Proteins 0.000 description 1
102100037505 Secretin Human genes 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
206010040070 Septic Shock Diseases 0.000 description 1
241000287219 Serinus canaria Species 0.000 description 1
206010043376 Tetanus Diseases 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
206010054094 Tumour necrosis Diseases 0.000 description 1
108091005906 Type I transmembrane proteins Proteins 0.000 description 1
108091005956 Type II transmembrane proteins Proteins 0.000 description 1
108010011107 Urotensins Proteins 0.000 description 1
102000026557 Urotensins Human genes 0.000 description 1
OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 1
230000004308 accommodation Effects 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
229960004150 aciclovir Drugs 0.000 description 1
150000008065 acid anhydrides Chemical class 0.000 description 1
239000012445 acidic reagent Substances 0.000 description 1
206010000496 acne Diseases 0.000 description 1
125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
238000001261 affinity purification Methods 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
150000001336 alkenes Chemical class 0.000 description 1
150000003973 alkyl amines Chemical class 0.000 description 1
108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
102000015395 alpha 1-Antitrypsin Human genes 0.000 description 1
229940024142 alpha 1-antitrypsin Drugs 0.000 description 1
102000004139 alpha-Amylases Human genes 0.000 description 1
108090000637 alpha-Amylases Proteins 0.000 description 1
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
229940024171 alpha-amylase Drugs 0.000 description 1
230000004075 alteration Effects 0.000 description 1
229940126575 aminoglycoside Drugs 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
229960003942 amphotericin b Drugs 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
229940126317 angiotensin II receptor antagonist Drugs 0.000 description 1
229950006323 angiotensin ii Drugs 0.000 description 1
238000010171 animal model Methods 0.000 description 1
238000000137 annealing Methods 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000002280 anti-androgenic effect Effects 0.000 description 1
239000000051 antiandrogen Substances 0.000 description 1
229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
239000003173 antianemic agent Substances 0.000 description 1
108010082685 antiarrhythmic peptide Proteins 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
229940124522 antiretrovirals Drugs 0.000 description 1
239000003903 antiretrovirus agent Substances 0.000 description 1
229960005348 antithrombin iii Drugs 0.000 description 1
208000011775 arteriosclerosis disease Diseases 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
229960001212 bacterial vaccine Drugs 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
108010005774 beta-Galactosidase Proteins 0.000 description 1
102000005936 beta-Galactosidase Human genes 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
238000007068 beta-elimination reaction Methods 0.000 description 1
102000006635 beta-lactamase Human genes 0.000 description 1
229960002537 betamethasone Drugs 0.000 description 1
UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
230000002902 bimodal effect Effects 0.000 description 1
230000000975 bioactive effect Effects 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
239000000090 biomarker Substances 0.000 description 1
230000006287 biotinylation Effects 0.000 description 1
238000007413 biotinylation Methods 0.000 description 1
229960001561 bleomycin Drugs 0.000 description 1
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
230000036765 blood level Effects 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
238000006664 bond formation reaction Methods 0.000 description 1
230000008468 bone growth Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
229960001736 buprenorphine Drugs 0.000 description 1
IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 description 1
229960001113 butorphanol Drugs 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
150000004657 carbamic acid derivatives Chemical class 0.000 description 1
125000005392 carboxamide group Chemical group NC(=O)* 0.000 description 1
150000007942 carboxylates Chemical group 0.000 description 1
235000021466 carotenoid Nutrition 0.000 description 1
150000001747 carotenoids Chemical class 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
239000013553 cell monolayer Substances 0.000 description 1
108091092356 cellular DNA Proteins 0.000 description 1
108091092328 cellular RNA Proteins 0.000 description 1
229940124587 cephalosporin Drugs 0.000 description 1
150000001780 cephalosporins Chemical class 0.000 description 1
239000013522 chelant Substances 0.000 description 1
AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
238000012412 chemical coupling Methods 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
239000002975 chemoattractant Substances 0.000 description 1
210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
238000005660 chlorination reaction Methods 0.000 description 1
LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
102000004358 claudin 14 Human genes 0.000 description 1
108090000995 claudin 14 Proteins 0.000 description 1
102000004295 claudin 16 Human genes 0.000 description 1
108090000840 claudin 16 Proteins 0.000 description 1
230000035602 clotting Effects 0.000 description 1
QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
229940068796 clozaril Drugs 0.000 description 1
229960004126 codeine Drugs 0.000 description 1
235000017471 coenzyme Q10 Nutrition 0.000 description 1
229960001338 colchicine Drugs 0.000 description 1
238000012875 competitive assay Methods 0.000 description 1
238000005094 computer simulation Methods 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
229960004544 cortisone Drugs 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
JJCFRYNCJDLXIK-UHFFFAOYSA-N cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 description 1
229960001140 cyproheptadine Drugs 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
229960000975 daunorubicin Drugs 0.000 description 1
230000006240 deamidation Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000007123 defense Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000022811 deglycosylation Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
238000010511 deprotection reaction Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
229960003957 dexamethasone Drugs 0.000 description 1
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
229950006137 dexfosfoserine Drugs 0.000 description 1
229960001985 dextromethorphan Drugs 0.000 description 1
125000005265 dialkylamine group Chemical group 0.000 description 1
229960002656 didanosine Drugs 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
238000002050 diffraction method Methods 0.000 description 1
HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
229960004166 diltiazem Drugs 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
ULAUBQTVYAVTFT-UHFFFAOYSA-N dinitro carbonate Chemical compound [O-][N+](=O)OC(=O)O[N+]([O-])=O ULAUBQTVYAVTFT-UHFFFAOYSA-N 0.000 description 1
MGHPNCMVUAKAIE-UHFFFAOYSA-N diphenylmethanamine Chemical compound C=1C=CC=CC=1C(N)C1=CC=CC=C1 MGHPNCMVUAKAIE-UHFFFAOYSA-N 0.000 description 1
206010013023 diphtheria Diseases 0.000 description 1
230000006806 disease prevention Effects 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
150000002019 disulfides Chemical class 0.000 description 1
ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
229960005426 doxepin Drugs 0.000 description 1
229960004679 doxorubicin Drugs 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
239000000890 drug combination Substances 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
239000013583 drug formulation Substances 0.000 description 1
238000007877 drug screening Methods 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000003511 endothelial effect Effects 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
230000007929 epithelial cell-cell adhesion Effects 0.000 description 1
210000004783 epithelial tight junction Anatomy 0.000 description 1
YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
229960003276 erythromycin Drugs 0.000 description 1
229930182833 estradiol Natural products 0.000 description 1
229960005309 estradiol Drugs 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
210000003722 extracellular fluid Anatomy 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
239000000835 fiber Substances 0.000 description 1
ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
229960000961 floxuridine Drugs 0.000 description 1
RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
229960004884 fluconazole Drugs 0.000 description 1
229960002011 fludrocortisone Drugs 0.000 description 1
AAXVEMMRQDVLJB-BULBTXNYSA-N fludrocortisone Chemical compound O=C1CC[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 AAXVEMMRQDVLJB-BULBTXNYSA-N 0.000 description 1
229940043075 fluocinolone Drugs 0.000 description 1
229960002949 fluorouracil Drugs 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
125000003838 furazanyl group Chemical group 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
229930182830 galactose Natural products 0.000 description 1
UHBYWPGGCSDKFX-VKHMYHEASA-N gamma-carboxy-L-glutamic acid Chemical compound OC(=O)[C@@H](N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-VKHMYHEASA-N 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
102000054766 genetic haplotypes Human genes 0.000 description 1
CEAZRRDELHUEMR-UHFFFAOYSA-N gentamicin Chemical class O1C(C(C)NC)CCC(N)C1OC1C(O)C(OC2C(C(NC)C(C)(O)CO2)O)C(N)CC1N CEAZRRDELHUEMR-UHFFFAOYSA-N 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
229960003711 glyceryl trinitrate Drugs 0.000 description 1
YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
239000010931 gold Substances 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
229940094892 gonadotropins Drugs 0.000 description 1
DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 1
229960002867 griseofulvin Drugs 0.000 description 1
229940029575 guanosine Drugs 0.000 description 1
230000035931 haemagglutination Effects 0.000 description 1
230000003394 haemopoietic effect Effects 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
239000000833 heterodimer Substances 0.000 description 1
108010059239 hirugen Proteins 0.000 description 1
239000000710 homodimer Substances 0.000 description 1
229920002674 hyaluronan Polymers 0.000 description 1
229960003160 hyaluronic acid Drugs 0.000 description 1
OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
229960000890 hydrocortisone Drugs 0.000 description 1
WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 1
229960001410 hydromorphone Drugs 0.000 description 1
229960001680 ibuprofen Drugs 0.000 description 1
125000002632 imidazolidinyl group Chemical group 0.000 description 1
125000002636 imidazolinyl group Chemical group 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
125000001841 imino group Chemical group [H]N=* 0.000 description 1
BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
229960004801 imipramine Drugs 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
238000010166 immunofluorescence Methods 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
229940027941 immunoglobulin g Drugs 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
230000001024 immunotherapeutic effect Effects 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
238000005462 in vivo assay Methods 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
239000005414 inactive ingredient Substances 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
229960000905 indomethacin Drugs 0.000 description 1
239000012442 inert solvent Substances 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
208000014674 injury Diseases 0.000 description 1
210000004692 intercellular junction Anatomy 0.000 description 1
210000004347 intestinal mucosa Anatomy 0.000 description 1
230000004068 intracellular signaling Effects 0.000 description 1
XMBWDFGMSWQBCA-RNFDNDRNSA-M iodine-131(1-) Chemical compound [131I-] XMBWDFGMSWQBCA-RNFDNDRNSA-M 0.000 description 1
125000001786 isothiazolyl group Chemical group 0.000 description 1
125000000842 isoxazolyl group Chemical group 0.000 description 1
229960004130 itraconazole Drugs 0.000 description 1
229960004125 ketoconazole Drugs 0.000 description 1
230000003907 kidney function Effects 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
229960003406 levorphanol Drugs 0.000 description 1
238000000670 ligand binding assay Methods 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
125000005647 linker group Chemical group 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000033001 locomotion Effects 0.000 description 1
229940040129 luteinizing hormone Drugs 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
238000013507 mapping Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
238000002483 medication Methods 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
229960001428 mercaptopurine Drugs 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
229910021645 metal ion Inorganic materials 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
230000011987 methylation Effects 0.000 description 1
238000007069 methylation reaction Methods 0.000 description 1
229960004584 methylprednisolone Drugs 0.000 description 1
229960002509 miconazole Drugs 0.000 description 1
244000005700 microbiome Species 0.000 description 1
230000004089 microcirculation Effects 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
NKAAEMMYHLFEFN-UHFFFAOYSA-M monosodium tartrate Chemical compound [Na+].OC(=O)C(O)C(O)C([O-])=O NKAAEMMYHLFEFN-UHFFFAOYSA-M 0.000 description 1
229960005181 morphine Drugs 0.000 description 1
125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
125000002757 morpholinyl group Chemical group 0.000 description 1
230000000420 mucociliary effect Effects 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
231100000017 mucous membrane irritation Toxicity 0.000 description 1
229940035363 muscle relaxants Drugs 0.000 description 1
210000004897 n-terminal region Anatomy 0.000 description 1
NETZHAKZCGBWSS-CEDHKZHLSA-N nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 description 1
229960000805 nalbuphine Drugs 0.000 description 1
229960005297 nalmefene Drugs 0.000 description 1
DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 1
229960003086 naltrexone Drugs 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
239000003887 narcotic antagonist Substances 0.000 description 1
229940100652 nasal gel Drugs 0.000 description 1
229920005615 natural polymer Polymers 0.000 description 1
PCJGZPGTCUMMOT-ISULXFBGSA-N neurotensin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 PCJGZPGTCUMMOT-ISULXFBGSA-N 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
229960001597 nifedipine Drugs 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
239000002777 nucleoside Substances 0.000 description 1
125000003835 nucleoside group Chemical group 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
238000006384 oligomerization reaction Methods 0.000 description 1
239000003399 opiate peptide Substances 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000008520 organization Effects 0.000 description 1
230000002188 osteogenic effect Effects 0.000 description 1
125000002971 oxazolyl group Chemical group 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
LDCYZAJDBXYCGN-UHFFFAOYSA-N oxitriptan Natural products C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 description 1
229960005118 oxymorphone Drugs 0.000 description 1
229940094443 oxytocics prostaglandins Drugs 0.000 description 1
238000012856 packing Methods 0.000 description 1
229960001789 papaverine Drugs 0.000 description 1
229960005489 paracetamol Drugs 0.000 description 1
108010005195 parathyroid hormone-related protein (107-111) Proteins 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000009054 pathological process Effects 0.000 description 1
150000002960 penicillins Chemical class 0.000 description 1
239000000863 peptide conjugate Substances 0.000 description 1
108010011903 peptide receptors Proteins 0.000 description 1
102000014187 peptide receptors Human genes 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
239000012071 phase Substances 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
USRGIUJOYOXOQJ-GBXIJSLDSA-N phosphothreonine Chemical compound OP(=O)(O)O[C@H](C)[C@H](N)C(O)=O USRGIUJOYOXOQJ-GBXIJSLDSA-N 0.000 description 1
102000020233 phosphotransferase Human genes 0.000 description 1
DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
230000006461 physiological response Effects 0.000 description 1
239000000467 phytic acid Substances 0.000 description 1
229940068041 phytic acid Drugs 0.000 description 1
235000002949 phytic acid Nutrition 0.000 description 1
125000004193 piperazinyl group Chemical group 0.000 description 1
125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
125000005936 piperidyl group Chemical group 0.000 description 1
QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
229960002702 piroxicam Drugs 0.000 description 1
210000002826 placenta Anatomy 0.000 description 1
229920000024 polymyxin B Polymers 0.000 description 1
229960005266 polymyxin b Drugs 0.000 description 1
108091033319 polynucleotide Proteins 0.000 description 1
102000040430 polynucleotide Human genes 0.000 description 1
239000002157 polynucleotide Substances 0.000 description 1
229920000098 polyolefin Polymers 0.000 description 1
229920001451 polypropylene glycol Polymers 0.000 description 1
IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 1
229960001289 prazosin Drugs 0.000 description 1
239000002243 precursor Substances 0.000 description 1
229960005205 prednisolone Drugs 0.000 description 1
OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
229960004618 prednisone Drugs 0.000 description 1
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
230000008569 process Effects 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
150000003147 proline derivatives Chemical class 0.000 description 1
125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
235000019419 proteases Nutrition 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
230000004224 protection Effects 0.000 description 1
230000004845 protein aggregation Effects 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
230000006916 protein interaction Effects 0.000 description 1
238000009163 protein therapy Methods 0.000 description 1
125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
KOUKXHPPRFNWPP-UHFFFAOYSA-N pyrazine-2,5-dicarboxylic acid;hydrate Chemical compound O.OC(=O)C1=CN=C(C(O)=O)C=N1 KOUKXHPPRFNWPP-UHFFFAOYSA-N 0.000 description 1
125000003373 pyrazinyl group Chemical group 0.000 description 1
125000003072 pyrazolidinyl group Chemical group 0.000 description 1
125000002755 pyrazolinyl group Chemical group 0.000 description 1
125000003226 pyrazolyl group Chemical group 0.000 description 1
125000002098 pyridazinyl group Chemical group 0.000 description 1
125000004076 pyridyl group Chemical group 0.000 description 1
125000000714 pyrimidinyl group Chemical group 0.000 description 1
125000000719 pyrrolidinyl group Chemical group 0.000 description 1
125000001422 pyrrolinyl group Chemical group 0.000 description 1
125000000168 pyrrolyl group Chemical group 0.000 description 1
229960001404 quinidine Drugs 0.000 description 1
230000008707 rearrangement Effects 0.000 description 1
239000003488 releasing hormone Substances 0.000 description 1
230000003252 repetitive effect Effects 0.000 description 1
238000009256 replacement therapy Methods 0.000 description 1
230000001850 reproductive effect Effects 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
229960000329 ribavirin Drugs 0.000 description 1
HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
238000007363 ring formation reaction Methods 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
238000007423 screening assay Methods 0.000 description 1
229960002101 secretin Drugs 0.000 description 1
OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 1
230000009834 selective interaction Effects 0.000 description 1
210000000697 sensory organ Anatomy 0.000 description 1
238000000926 separation method Methods 0.000 description 1
229940076279 serotonin Drugs 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
230000009645 skeletal growth Effects 0.000 description 1
210000002027 skeletal muscle Anatomy 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
JJICLMJFIKGAAU-UHFFFAOYSA-N sodium;2-amino-9-(1,3-dihydroxypropan-2-yloxymethyl)-3h-purin-6-one Chemical compound [Na+].N1C(N)=NC(=O)C2=C1N(COC(CO)CO)C=N2 JJICLMJFIKGAAU-UHFFFAOYSA-N 0.000 description 1
RMLUKZWYIKEASN-UHFFFAOYSA-M sodium;2-amino-9-(2-hydroxyethoxymethyl)purin-6-olate Chemical compound [Na+].O=C1[N-]C(N)=NC2=C1N=CN2COCCO RMLUKZWYIKEASN-UHFFFAOYSA-M 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
229960002256 spironolactone Drugs 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000012289 standard assay Methods 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
238000003860 storage Methods 0.000 description 1
125000000565 sulfonamide group Chemical group 0.000 description 1
238000006277 sulfonation reaction Methods 0.000 description 1
230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
229920001059 synthetic polymer Polymers 0.000 description 1
210000004876 tela submucosa Anatomy 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
229940040944 tetracyclines Drugs 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
125000001113 thiadiazolyl group Chemical group 0.000 description 1
125000000335 thiazolyl group Chemical group 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
150000007970 thio esters Chemical class 0.000 description 1
150000003556 thioamides Chemical class 0.000 description 1
125000003396 thiol group Chemical group [H]S* 0.000 description 1
125000005505 thiomorpholino group Chemical group 0.000 description 1
125000004568 thiomorpholinyl group Chemical group 0.000 description 1
230000001732 thrombotic effect Effects 0.000 description 1
239000005495 thyroid hormone Substances 0.000 description 1
229940036555 thyroid hormone Drugs 0.000 description 1
230000025934 tissue morphogenesis Effects 0.000 description 1
229930003799 tocopherol Natural products 0.000 description 1
239000011732 tocopherol Substances 0.000 description 1
125000002640 tocopherol group Chemical class 0.000 description 1
235000019149 tocopherols Nutrition 0.000 description 1
125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
229960005294 triamcinolone Drugs 0.000 description 1
GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
125000001425 triazolyl group Chemical group 0.000 description 1
101150044170 trpE gene Proteins 0.000 description 1
150000003669 ubiquinones Chemical class 0.000 description 1
231100000402 unacceptable toxicity Toxicity 0.000 description 1
241000712461 unidentified influenza virus Species 0.000 description 1
210000003708 urethra Anatomy 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
239000000780 urotensin Substances 0.000 description 1
230000002792 vascular Effects 0.000 description 1
208000019553 vascular disease Diseases 0.000 description 1
210000000264 venule Anatomy 0.000 description 1
229960001722 verapamil Drugs 0.000 description 1
229960004854 viral vaccine Drugs 0.000 description 1
238000002424 x-ray crystallography Methods 0.000 description 1
229960000523 zalcitabine Drugs 0.000 description 1
229960002555 zidovudine Drugs 0.000 description 1
HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1